Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CEBPA Antikörper (AA 1-124)

CEBPA Reaktivität: Human WB, ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN7147076
  • Target Alle CEBPA Antikörper anzeigen
    CEBPA (CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA))
    Bindungsspezifität
    • 20
    • 14
    • 12
    • 9
    • 9
    • 8
    • 7
    • 5
    • 4
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 1-124
    Reaktivität
    • 101
    • 81
    • 72
    • 8
    • 6
    • 5
    • 5
    • 5
    • 4
    • 3
    • 3
    • 1
    • 1
    Human
    Wirt
    • 104
    • 4
    • 1
    • 1
    Kaninchen
    Klonalität
    • 98
    • 12
    Polyklonal
    Konjugat
    • 47
    • 9
    • 6
    • 6
    • 6
    • 6
    • 6
    • 6
    • 5
    • 4
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser CEBPA Antikörper ist unkonjugiert
    Applikation
    • 68
    • 40
    • 20
    • 16
    • 15
    • 15
    • 10
    • 5
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
    Kreuzreaktivität
    Human
    Aufreinigung
    >95%, Protein G purified
    Immunogen
    Recombinant Human CCAAT/enhancer-binding protein alpha protein (1-124AA)
    Isotyp
    IgG
    Top Product
    Discover our top product CEBPA Primärantikörper
  • Applikationshinweise
    Recommended dilution: WB:1:500-1:5000, IHC:1:20-1:200,
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Preservative: 0.03 % Proclin 300
    Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C,-80 °C
    Informationen zur Lagerung
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Target
    CEBPA (CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA))
    Andere Bezeichnung
    CEBPA (CEBPA Produkte)
    Synonyme
    C/EBP-alpha antikoerper, CEBP antikoerper, C/ebpalpha antikoerper, CBF-A antikoerper, Cebp antikoerper, DBPCEP antikoerper, c/ebpa antikoerper, cb1062 antikoerper, wu:fj20f03 antikoerper, C/EBP antikoerper, C/EBPalpha antikoerper, xC/EBP antikoerper, cC/EBP antikoerper, C/EBP alpha antikoerper, CCAAT/enhancer binding protein alpha antikoerper, CCAAT/enhancer binding protein (C/EBP), alpha antikoerper, CCAAT/enhancer binding protein alpha L homeolog antikoerper, CEBPA antikoerper, Cebpa antikoerper, cebpa antikoerper, cebpa.L antikoerper
    Hintergrund

    Background: Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5\\\'-T[TG]NNGNAA[TG]-3\\\' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Downregulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex (PubMed:14660596). In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity).

    Aliases: Apoptotic cysteine protease antibody, Apoptotic protease Mch 5 antibody, C/EBP alpha antibody, C/ebpalpha antibody, CAP4 antibody, Caspase 8 precursor antibody, CBF-A antibody, CCAAT Enhancer Binding Protein alpha antibody, CCAAT/enhancer binding protein (C/EBP), alpha antibody, CCAAT/enhancer-binding protein alpha antibody, CEBP antibody, CEBP A antibody, CEBP alpha antibody, Cebpa antibody, CEBPA_HUMAN antibody, FADD homologous ICE/CED 3 like protease antibody, FADD like ICE antibody, FLICE antibody, ICE like apoptotic protease 5 antibody, ICE8 antibody, MACH antibody, MCH5 antibody, MORT1 associated CED 3 homolog antibody

    UniProt
    P49715
    Pathways
    Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation
Sie sind hier: